Objective To observe the effect of cisplatin in bletilla hyacinthine particle chemotherapy combined with 125I brachytherapy on short-and long-term outcomes and the toxic and side effects in advanced gastric cancer. Methods One hundred seventy-six patients with stage Ⅱ or stage Ⅲ advanced gastric cancer underwent curative surgical resection were included in this study. They were randomly divided into brachytherapy and chemotherapy group (n=48), intraperitoneal chemotherapy group (n=32) and intravenous chemotherapy group (n=48), and other patients who abandoned radiotherapy and chemotherapy and signed informed consent form by themselves were considered as control group (n=48). The short-and long-term outcomes and the toxic and side effects were observed and the survival of all patients was analyzed by Kaplan-Meier method and Log-Rank test. Results For short-term outcomes, the total effective rate in 4 groups were 95.83%, 71.88%, 64.58% and 52.08% respectively, and the difference was significant (Plt;0.05). For long-term outcomes, the 3 -and 5-year mortality rate was 37.50% and 56.30%, and 5-year median survival time was (14±4.51) months (95%CI: 14.419-4.512) in brachytherapy and chemotherapy group patients. The 3- and 5-year mortality rate was 78.12%and 93.75%and 5year median survival time was (10.6±1.13) months (95%CI: 10.620-1.163) in intraperitoneal chemotherapy group patients. The 3-and 5-year mortality rate was 79.21%and 95.80%and 5-year median survival time was (11±3.10) months (95%CI: 11.130-3.162) in intravenous chemotherapy group patients. The 3-and 5-year mortality rate was 87.50%and 95.83% and 5-year median survival time was (9±2.30) months (95%CI: 10.024-1.180) in control group patients. Compared with the vein chemotherapy group, the short distance puts the chemotherapy group disgusting vomit, the marrow to suppress, the liver function harm, the kidney function harm formation rate to reduce obviously (Plt;0.05). Conclusion Cisplatin in bletilla hyacinthine particle chemotherapy combined with 125I brachytherapy can reduce the toxic and side effects of drugs and prolong survival time of patients with advanced gastric cancer.
目的 研究氯胺酮能否降低咪達唑侖誘導急診危重患者氣管插管對血壓的影響。 方法 將2010年6月－2011年12月收治的56例急診危重呼吸衰竭成年患者，隨機分成咪達唑侖+芬太尼（MF）組和咪達唑侖+氯胺酮（MK）組，氣管插管前咪達唑侖0.05 mg/kg靜脈注入，然后MF組芬太尼2 μg/kg靜脈注入，MK組氯胺酮0.5 mg/kg靜脈注入，待患者達鎮靜狀態后實施氣管插管。記錄用藥前和插管后10 min的收縮壓（SBP）、舒張壓（DBP）、平均動脈壓（MAP）、心率（HR）的變化，觀察低血壓的發生情況。 結果 實施藥物誘導氣管插管后血壓下降以MF組更明顯（P＜0.01）。低血壓發生率MF組為51.7%，MK組為18.5%，兩組比較差異有統計學意義（χ2=6.715，P=0.01）。 結論 急診危重患者氣管插管應用氯胺酮可減少咪達唑侖所致低血壓的發生率。